16th Aug 2007 07:00
Advanced Medical Solutions Grp PLC16 August 2007 For immediate release 16 August 2007 Advanced Medical Solutions Group plc ("AMS" or "the Company") Major London Teaching Hospital Trust implements ActivHeal(R) Trading Update / Interim Results Date Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company, today announces that following a review of theirwoundcare product formulary, University College London Hospitals (UCLH) NHSFoundation Trust has adopted products from the ActivHeal(R) advanced woundcareproduct range and these are now in routine use. Granted Foundation Trust status in 2004 and comprising seven separate hospitalsites, UCLH NHS Trust is a major London teaching centre and contracts with 300Primary Care Trusts. ActivHeal(R) is a value range of products provided directly to the NHS by AMS asa first line therapy for routine wounds. These complement the use of its newtechnologies such as silver alginate for treating more difficult wounds whichare sold through strategic partners. The ActivHeal(R) range offers equivalent technical and clinical performance tosimilar branded products but at a substantially reduced cost thereby deliveringreal and immediate savings to the NHS. This saving is estimated to be of theorder of £25 million per year in the UK which helps to balance budgets andafford new technologies for problematic cases. At the end of 2006 over 40 NHSHospital and Primary Care Trusts were using ActivHeal(R) and this number isincreasing steadily. Trading update and Interim Results announcement date: The Company will announce its Interim Results for the six months ended 30th June2007 on Tuesday 4th September 2007 which, as indicated in the tradingannouncement on 6th June 2007, are expected to show maiden first half profits.Since then trading has continued to be strong and a further update will be givenon 4th September. An analyst briefing will be held at 10:00 am at Buchanan Communications, 45,Moorfields, London EC2 on the day of the announcement. Advanced Medical Solutions Group plc confirms that, for the purposes of AIM Rule26, the Company's website address is http://www.admedsol.com/corporate/Aim26/index.html Commenting on this announcement, Dr. Don Evans, Chief Executive of AMS, stated:"I am delighted that we have added a major teaching centre such as UCLH to thegrowing number of Trusts that have adopted the ActivHeal(R) offering as a way ofmanaging costs without compromising patient care." Sarah Lewis, Tissue Viability Nurse, UCLH, added: "Following a review of ourwoundcare product formulary, the dressings review group evaluated products froma number of companies. After a three month user trial, ActivHeal(R) productswere added to our formulary based on evidence presented to the Use of MedicinesCommittee. We have not experienced any problem with the products. "The AMS clinical nurse team assisted us in making a successful implementationwith product training throughout the Trust, provision of posters, woundcareeducation modules and by running a study day." -- ENDS -- For further information, please contact: Advanced Medical Solutions Group plc +44 (0) 01606 545508Don Evans (Chief Executive Officer)Mary Tavener (Group Finance Director)www.admedsol.com Buchanan Communications +44 (0) 020 7466 5000Mark Court/Mary-Jane Johnson Landsbanki Securities (UK) Ltd +44 (0) 020 7426 9000Shaun Dobson / Xavier DeMol Notes for Editors: Advanced Medical Solutions is a UK based company developing and providingleading edge technology to the $15 billion global woundcare market. Founded in 1991 and quoted on AIM, the Company is focused on the design,development, manufacture and sale of advanced woundcare dressings and productsfor closing wounds and sealing tissue. AMS provides a full range of advanced woundcare products for sale in hospital,nursing home and community care markets. The main indications are for chronicwounds such as ulcers and pressure sores. These products pioneer the concept ofmoist wound healing to allow wounds to heal faster and with less pain andscarring if they remain moist. They protect the wound, deal with tissue fluidsand provide an optimal environment for healing to occur. AMS' resources ensurea unique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove a product from design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products based uponcyanoacrylate adhesive technology which allow the closure of wounds followingtrauma or surgical incisions, or seal skin to protect against breakdown or woundinfection. These products address the emerging tissue adhesives and sealantssegment of the wound closure market. AMS' technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Advanced Medical Solutions Group